{
  "symbol": "VRTX",
  "year": 2023,
  "metrics": {
    "mdna_sentiment": 0.1679,
    "outlook_sentiment": 0.1969,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.223
  },
  "top_positive": [
    {
      "sent": "As of January\u00a031, 2023, the registrant had 257,091,441 shares of common stock outstanding.",
      "score": 0.7351
    },
    {
      "sent": "Yes \u2610 No\u00a0\u2612 The aggregate market value of the registrant\u2019s common stock held by non-affiliates of the registrant based on the closing price on June 30, 2022 (the last business day of the registrant\u2019s most recently completed second fiscal quarter of 2022) was $ 71.8 billion.",
      "score": 0.4404
    },
    {
      "sent": "Such statements may relate to: \u2022 our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses, and other gains and losses; \u2022 our expectations regarding clinical trials, including expectations for patient enrollment, development timelines, the expected timing of data from our ongoing and planned clinical trials, and regulatory authority filings and other submissions for our therapies; \u2022 our ability to maintain and obtain adequate reimbursement for our products, our ability to launch, commercialize and market our products or any of our other therapies for which we obtain regulatory approval and our ability to obtain label expansions for existing therapies; \u2022 our expectations regarding our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines and providing improved treatment options for people who are already eligible for one of our medicines; 59 \u2022 the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings; \u2022 our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our therapies for further investigation, clinical trials or potential use as a treatment; \u2022 our plans to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators; \u2022 our beliefs regarding the approximate patient populations for the disease areas on which we focus; \u2022 the potential benefits and therapeutic scope of our acquisitions and collaborations, including our acquisition of ViaCyte and its potential to accelerate development of our stem-cell based T1D programs; \u2022 the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations; \u2022 potential business development activities, including the identification of potential collaborative partners or acquisition targets; \u2022 our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to products; \u2022 potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management program; \u2022 our expectations regarding the amount of cash to generated by operations, our cash balance and expected generation and interest income; \u2022 our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets; \u2022 our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs; \u2022 our plans to expand, strengthen, and invest in our global supply chains and manufacturing infrastructure and capabilities, including for cell and gene therapies; \u2022 our ability to attract and retain skilled personnel; \u2022 our expectations involving governmental cost containment and other regulatory efforts; \u2022 our expectations surrounding the competitive landscape facing our products and product candidates; \u2022 our expectations regarding the effect of COVID-19 on, among other things, our financial performance, liquidity, business and operations, including manufacturing, supply chain, research and development activities and pipeline programs; and \u2022 our liquidity and our expectations regarding the possibility of raising additional capital.",
      "score": 0.9947
    },
    {
      "sent": "Such statements may relate to: \u2022 our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses, and other gains and losses; \u2022 our expectations regarding clinical trials, including expectations for patient enrollment, development timelines, the expected timing of data from our ongoing and planned clinical trials, and regulatory authority filings and other submissions for our therapies; \u2022 our ability to maintain and obtain adequate reimbursement for our products, our ability to launch, commercialize and market our products or any of our other therapies for which we obtain regulatory approval and our ability to obtain label expansions for existing therapies; \u2022 our expectations regarding our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines and providing improved treatment options for people who are already eligible for one of our medicines; 59 \u2022 the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings; \u2022 our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our therapies for further investigation, clinical trials or potential use as a treatment; \u2022 our plans to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators; \u2022 our beliefs regarding the approximate patient populations for the disease areas on which we focus; \u2022 the potential benefits and therapeutic scope of our acquisitions and collaborations, including our acquisition of ViaCyte and its potential to accelerate development of our stem-cell based T1D programs; \u2022 the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations; \u2022 potential business development activities, including the identification of potential collaborative partners or acquisition targets; \u2022 our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to products; \u2022 potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management program; \u2022 our expectations regarding the amount of cash to generated by operations, our cash balance and expected generation and interest income; \u2022 our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets; \u2022 our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs; \u2022 our plans to expand, strengthen, and invest in our global supply chains and manufacturing infrastructure and capabilities, including for cell and gene therapies; \u2022 our ability to attract and retain skilled personnel; \u2022 our expectations involving governmental cost containment and other regulatory efforts; \u2022 our expectations surrounding the competitive landscape facing our products and product candidates; \u2022 our expectations regarding the effect of COVID-19 on, among other things, our financial performance, liquidity, business and operations, including manufacturing, supply chain, research and development activities and pipeline programs; and \u2022 our liquidity and our expectations regarding the possibility of raising additional capital.",
      "score": 0.9947
    },
    {
      "sent": "Such statements may relate to: \u2022 our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses, and other gains and losses; \u2022 our expectations regarding clinical trials, including expectations for patient enrollment, development timelines, the expected timing of data from our ongoing and planned clinical trials, and regulatory authority filings and other submissions for our therapies; \u2022 our ability to maintain and obtain adequate reimbursement for our products, our ability to launch, commercialize and market our products or any of our other therapies for which we obtain regulatory approval and our ability to obtain label expansions for existing therapies; \u2022 our expectations regarding our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines and providing improved treatment options for people who are already eligible for one of our medicines; 59 \u2022 the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings; \u2022 our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our therapies for further investigation, clinical trials or potential use as a treatment; \u2022 our plans to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators; \u2022 our beliefs regarding the approximate patient populations for the disease areas on which we focus; \u2022 the potential benefits and therapeutic scope of our acquisitions and collaborations, including our acquisition of ViaCyte and its potential to accelerate development of our stem-cell based T1D programs; \u2022 the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations; \u2022 potential business development activities, including the identification of potential collaborative partners or acquisition targets; \u2022 our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to products; \u2022 potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management program; \u2022 our expectations regarding the amount of cash to generated by operations, our cash balance and expected generation and interest income; \u2022 our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets; \u2022 our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs; \u2022 our plans to expand, strengthen, and invest in our global supply chains and manufacturing infrastructure and capabilities, including for cell and gene therapies; \u2022 our ability to attract and retain skilled personnel; \u2022 our expectations involving governmental cost containment and other regulatory efforts; \u2022 our expectations surrounding the competitive landscape facing our products and product candidates; \u2022 our expectations regarding the effect of COVID-19 on, among other things, our financial performance, liquidity, business and operations, including manufacturing, supply chain, research and development activities and pipeline programs; and \u2022 our liquidity and our expectations regarding the possibility of raising additional capital.",
      "score": 0.9947
    }
  ],
  "top_negative": [
    {
      "sent": "Patients with pain can be categorized as suffering from one of three types of pain: acute pain, chronic neuropathic pain (caused primarily by damage or dysfunction of the nervous system) or chronic musculoskeletal pain (caused primarily by damage to muscle, joints or bone).",
      "score": -0.9833
    },
    {
      "sent": "Patients with pain can be categorized as suffering from one of three types of pain: acute pain, chronic neuropathic pain (caused primarily by damage or dysfunction of the nervous system) or chronic musculoskeletal pain (caused primarily by damage to muscle, joints or bone).",
      "score": -0.9833
    },
    {
      "sent": "Patients with pain can be categorized as suffering from one of three types of pain: acute pain, chronic neuropathic pain (caused primarily by damage or dysfunction of the nervous system) or chronic musculoskeletal pain (caused primarily by damage to muscle, joints or bone).",
      "score": -0.9833
    }
  ],
  "forward_snippets": [
    "DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive proxy statement for the 2023 Annual Meeting of Shareholders, which we expect to hold on May 17, 2023, are incorporated by reference into Part\u00a0III of this Annual Report on Form\u00a010-K.",
    "We have four approved medicines that treat the underlying cause of cystic fibrosis (\u201cCF\u201d), a life-threatening genetic disease, and we continue to focus on developing additional treatments for CF.",
    "Beyond CF, we have a pipeline that includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies.",
    "We believe this new triple-combination has the potential to provide enhanced benefits to CF patients who have at least one mutation in their CFTR gene.",
    "Our Clinical Trial Application (\u201cCTA\u201d) in Canada for our second program in T1D, VX-264, in which the implanted islet cells are encapsulated in an immunoprotective device, was authorized and we plan to begin screening, enrollment and dosing in Canada in the coming months.",
    "We are conducting IND-enabling studies for our first in vivo gene-editing therapy for Duchenne Muscular Dystrophy (\u201cDMD\u201d), and we expect to submit an IND for this program in 2023."
  ]
}